Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

NCT04913922 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine Injection
DRUG: Nivolumab
DRUG: Relatlimab

Sponsor

Ludwig-Maximilians - University of Munich